Navigation Links
Orchid Cellmark Applauds Expansion of Federal Forensic DNA Identity Testing to Include All Arrestees

- New Federal Rules Authorizing DNA Testing of Federal Arrestees Expected

to Boost Law Enforcement's Ability to Combat Crime -

- Complements Recent Moves by States to Expand their DNA Databases -

PRINCETON, N.J., April 18 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, today highlighted new federal regulations previewed by the U.S. Justice Department that are expected to greatly expand the forensic DNA testing of federal arrestees and illegal immigrants. The proposed regulations will authorize DNA testing and inclusion in the federal Combined DNA Index System (CODIS) database of DNA profiles of all federal arrestees and illegal immigration detainees. Currently, the federal government only includes convicted felons in the CODIS database. The proposed new regulations implement provisions of the Violence Against Women Act passed by the U.S. Congress in late 2005. They are expected to result in an additional 1.2 million DNA profiles being added to CODIS annually.

"We welcome these new regulations that we expect to increase the use of forensic DNA testing, now considered by law enforcement authorities as a fundamental crime-fighting tool," said Thomas Bologna, President and Chief Executive Officer of Orchid Cellmark. "Our support reflects our experience as a major DNA testing provider both here and in the U.K., where the DNA database includes most arrestees and approximately half of crime scene evidence samples successfully match a profile already in the DNA database, contributing significantly to crime fighting efforts. We believe further expansion of forensic DNA testing through these regulations will enable U.S. law enforcement officials to solve crimes more rapidly and will also help prevent the repeat offenses committed by some criminals before they are convicted."

Thirteen states have already passed laws to include many arrestees in their DNA databanks, including California, Virginia, Maryland, Texas, Louisiana, New Mexico, Alaska, Arizona, Kansas, South Dakota, North Dakota, Minnesota, and Tennessee. California will begin collecting DNA from all felony arrestees in 2009, and legislation expanding forensic DNA testing is currently under consideration in an additional 21 states.

Mr. Bologna continued, "While we appreciate the concerns of some groups that database information could be misused, our long experience in working with the states and the federal government gives us confidence that the possibility of abuse is low, especially since the profiles included in the database do not include information relevant to health or other genetic traits, and the new regulations will specifically preclude these types of uses. As a long-established leader and innovator in the provision of forensic DNA testing services, Orchid Cellmark intends to work closely with appropriate law enforcement officials to help supply the expanded DNA testing expected to result from the new federal regulations, which we believe will further the goal of improving the effectiveness and equity of our criminal justice system."

Orchid Cellmark, one of the most respected forensic DNA testing firms in the world, is the only publicly traded firm focusing specifically on forensic DNA and other DNA identity testing.

Orchid Cellmark's U.S.-based forensic laboratories have received the prestigious accreditation of the American Society of Crime Laboratory Directors/Laboratory Accreditation Board (ASCLD/LAB). Orchid Cellmark's laboratories are also certified by the American Association of Blood Banks (AABB) and its Dallas and Nashville forensic laboratories are accredited to the International ISO/IEC 17025 Standard.

About the DNA Profiles Used in the CODIS Database

Similar to fingerprints, DNA profiles can be catalogued in a criminal justice database and DNA recovered from crime scene evidence can then be matched to profiles in the DNA database to identify possible suspects. The confidentiality of individual genetic profiles included in criminal justice databases for purposes other than confirming identity is not at risk since the DNA profiles that are produced for law enforcement purposes are only suitable for confirming identity, not for assessing other attributes of the individual. This reflects the fact that the DNA identity markers used for CODIS testing are specifically selected to preclude testing for any genetic markers that might contain information about an individual's health, susceptibility to medical conditions or other genetically linked traits.

About the CODIS Database

CODIS, the Combined DNA Index System, is the U.S. forensic DNA database system that includes a criminal offender database of DNA profiles, a forensic case evidence database from criminal evidence in unsolved crimes, a database of DNA profiles from unidentified decedents found by law enforcement, and a database of parents and relatives of missing persons. CODIS is a pyramid of local criminal offender and forensic case evidence databases maintained by local police crime labs (LDIS), state controlled databases (SDIS), and a single federal database which is called the National DNA Indexing System (or NDIS). Today, over 170 public law enforcement laboratories participate in NDIS across the United States. More information about CODIS can be found at For more information on the status of DNA testing legislation in the U.S., see

About Orchid Cellmark

Orchid Cellmark is a leading provider of identity DNA testing services for the human identity and agriculture markets. In the human identity area, the company provides DNA testing services for forensic, family relationship and security applications. In the agriculture field, Orchid Cellmark provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the world-renowned Cellmark brand that has been associated with exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at

All statements in this press release that are not historical are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the expectation that the proposed regulations regarding DNA testing will result in an additional 1.2 million DNA profiles being added to CODIS each year, the expectation that the proposed regulations regarding DNA testing will increase the use of forensic DNA testing, the belief that expansion of forensic DNA testing through these regulations will enable U.S. law enforcement officials to solve crimes more rapidly and will also help prevent the repeat offenses committed by some criminals before they are convicted, and the belief that these regulations will further the goal of improving the effectiveness and equity of the criminal justice system. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal funds, the timing and amount of contracts put up for bid, and Orchid Cellmark's ability to successfully offer its services directly to U.K. police forces. These risks and other additional factors affecting these forward-looking statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.


Investors: Media:

Mary Bashore Barbara Lindheim

Orchid Cellmark Inc. GendeLLindheim BioCom Partners

(609) 750-2324 (212) 918-4650

SOURCE Orchid Cellmark Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Orchid Cellmark Appoints James F. Smith Chief Financial Officer
2. Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007
3. Orchid Cellmark to Purchase ReliaGene Technologies, Inc.
4. FRC Applauds New Ballot Initiative for Cures Without Cloning
5. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
6. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
9. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
10. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
11. Genzyme Begins Major Expansion of Boston Manufacturing Facility
Post Your Comments:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... At its ... Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has ... was a member of the winning team for the 2015 Breakthrough Prize in Fundamental ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography (sEMG) ... tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase III ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:5/23/2017)... , May 23, 2017  Hunova, the first robotic gym for the ... been officially launched in Genoa, Italy . The first ... and the USA . The technology was developed ... market by the IIT spin-off Movendo Technology thanks to a 10 million ... News Release, please click: ...
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
Breaking Biology News(10 mins):